8-K: IMAC Holdings Divests Ignite Proteomics to Satisfy Debt

IMAC Holdings, Inc. has turned over its Ignite Proteomics subsidiary and related assets to a collateral agent, satisfying senior secured notes and addressing a default.

Summary

• IMAC Holdings, Inc. (the Company) defaulted on senior secured notes issued on December 19, 2025.
• To resolve this default, the Company entered into a Voluntary Turnover, Retention in Satisfaction and Release Agreement on March 11, 2026.
• Under this agreement, IMAC is voluntarily turning over 100% of the equity interests of its subsidiary, Ignite Proteomics LLC (Ignite), and all assets related to Ignite's business (Ignite Assets) to Cavalry Fund I SPV I LP, acting as the collateral agent for the noteholders.
• This turnover and retention of Ignite Assets by the collateral agent fully satisfies the senior secured notes and obligations owed to the noteholders.
• The agreement acknowledges a proposed sale of the Ignite Assets to Aditxt, Inc. (ADTX) for a stated value of at least $35 million.
• ADTX simultaneously entered into a Securities Purchase Agreement to sell a new series of convertible preferred stock (Series A-2) for an aggregate of $36,000,000, which will be deemed paid by the transfer of Ignite Assets from the investors (who are also the noteholders) to ADTX, potentially with a cash payment.
• IMAC has cancelled all indebtedness owed by Ignite to IMAC or its other subsidiaries, totaling $808,516.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative for IMAC Holdings, Inc. The company is in default, divesting a key subsidiary to satisfy debt, and faces substantial ongoing liabilities and legal challenges, indicating severe financial distress.

Positives

• Full satisfaction of approximately $8.5 million in senior secured notes, resolving a default event.
• Mutual release of claims between IMAC and the noteholders related to the satisfaction of the Notes.
• Cancellation of all indebtedness owed by Ignite Proteomics LLC to IMAC or its other subsidiaries, amounting to $808,516.

Negatives

• IMAC Holdings, Inc. was in default of its obligations under senior secured notes.
• The company is divesting 100% of its equity interest in its subsidiary, Ignite Proteomics LLC, and all related assets.
• Significant outstanding liabilities remain for IMAC, including $6,106,811.58 in accounts payable and accrued expenses, and $4,009,206 related to discontinued operations.
• IMAC Holdings, Inc. has not filed tax returns for 2023, 2024, and 2025.

Risks

• Ongoing Medicare audits for discontinued operations, with potential overpayment requests totaling approximately $4.3 million ($2.7 million for Progressive Health, $0.5 million for Advantage Therapy, and $1.1 million for IMAC St. Louis).
• Civil Investigative Demand from the U.S. Attorneys Office for the Middle District of Tennessee relating to billing practices at former Kentucky clinic locations, with IMAC believing claims pertain to independently owned clinic entities.
• Unfiled tax returns for 2023, 2024, and 2025, despite management's expectation of no taxes owed due to net losses.
• The lease for Ignite Proteomics' lab space, expiring in September 2026, is still under IMAC's name and requires transfer to Ignite Proteomics (now under ADTX ownership).

Future Outlook

IMAC Holdings will cease to use the Ignite Assets and will assist the Collateral Agent in obtaining title. ADTX will acquire these assets and issue convertible preferred stock. ADTX has provisions for stockholder approval for conversion shares and piggyback registration rights for investors. IMAC expects no taxes owed for 2023-2025 due to net losses.

Management Comments

• IMAC Holdings has cooperated fully with the inquiry and believes the claims at issue, to the extent they have merit, pertain to the independently owned clinic entities rather than to IMAC Holdings or its subsidiary.
• IMAC does not expect to owe taxes, having had a net loss each year.

Industry Context

StockSavvy.ai notes that this transaction reflects a strategic divestiture by IMAC Holdings to address significant debt and default issues, a common occurrence for companies facing financial distress. For Aditxt, Inc., the acquisition of Ignite Proteomics LLC represents an expansion or strategic pivot, potentially in the proteomics or related healthcare technology sector, funded through convertible preferred stock. The structure of the deal, involving a collateral agent and debt satisfaction through asset transfer, highlights the challenges faced by smaller public companies in managing debt and maintaining operational viability.

Management Changes

Corporate Governance

Legal Proceedings

• Third Party Audit: Ongoing audits by CMS contractors for discontinued operations, recommending overpayments of approximately $2.7 million (Progressive Health), $0.5 million (Advantage Therapy), and $1.1 million (IMAC St. Louis). Appeals are in various stages, including federal court and Medicare Appeals Council.
• Civil Investigative Demand: Received from the U.S. Attorneys Office for the Middle District of Tennessee relating to billing practices at former Kentucky clinic locations. IMAC believes claims pertain to independently owned clinic entities, not IMAC Holdings or its subsidiary.

Related Party Transactions

• Cavalry Fund I SPV I LP acts as both the collateral agent for IMAC's noteholders and a buyer of ADTX's Series A-2 convertible preferred stock, facilitating the transfer of Ignite Assets to ADTX in satisfaction of IMAC's debt. This arrangement involves the same entity in multiple roles across the transaction.

Stakeholder Impact

• Shareholders (IMAC): Significant negative impact due to default, loss of a key subsidiary, and ongoing financial/legal uncertainties.
• Noteholders (IMAC): Positive impact as their senior secured notes are fully satisfied through the asset turnover.
• Shareholders (ADTX): Potential dilutive effect from the issuance of convertible preferred stock, but also potential for growth from the acquisition of Ignite Proteomics.
• Employees (Ignite Proteomics): Transition of employment from IMAC to Ignite (under ADTX ownership), potentially ensuring job continuity but under new management.
• Creditors (IMAC): Other creditors may face uncertainty given the company's financial distress and the satisfaction of senior secured debt through asset divestiture.

Next Steps

• IMAC and the Collateral Agent to proceed with the sale of Ignite Assets to ADTX.
• ADTX to issue Series A-2 convertible preferred stock to investors.
• IMAC to cease use of Relevant Collateral and assist Collateral Agent in obtaining title.
• IMAC to continue appeals for Medicare overpayment claims.
• IMAC to cooperate with Civil Investigative Demand.
• ADTX to secure listing or designation for quotation of all Underlying Securities on an Eligible Market.
• ADTX to potentially seek stockholder approval for the issuance of conversion shares if the conversion price falls below the market price after one year.

Key Dates

Recommendation

The filing reveals IMAC Holdings, Inc. is in severe financial distress, evidenced by its default on senior secured notes and the necessity to divest its entire Ignite Proteomics subsidiary and related assets to satisfy this debt. While the debt is satisfied, the company loses a significant asset and still carries substantial other liabilities and faces multiple ongoing legal and regulatory challenges, including significant Medicare audit claims and a Civil Investigative Demand. The lack of filed tax returns for three years, even with expected net losses, indicates operational and compliance weaknesses. These factors collectively point to a highly unfavorable financial and operational outlook for IMAC Holdings, making it a 'sell' for a seasoned investor.

Keywords

IMAC Holdings, Aditxt, Ignite Proteomics, SEC filing, 8-K, debt default, asset sale, subsidiary divestiture, convertible preferred stock, financial distress, healthcare, proteomics, corporate governance, Medicare audit, legal proceedings